Oric Pharmaceuticals, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA, 94080
Mailing Address
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA, 94080
Phone
(650) 388-5600
Fiscal Year End
1231
EIN
471787157
Financial Overview
FY2025
-$127.85M
Net Income
$408.89M
Total Assets
$59.41M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 4 Insider stock transaction report | February 26, 2026 | View on SEC |
| 8-K Current report of material events | February 23, 2026 | View on SEC |
| 424B5 Prospectus supplement | February 23, 2026 | View on SEC |
| 10-K Annual financial report | February 23, 2026 | View on SEC |
| 8-K Current report of material events | February 23, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 21, 2026 | View on SEC |
| 4 Insider stock transaction report | January 20, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
Annual Reports
10-K
February 23, 2026
- Advancing two lead drug candidates, Rinzimetostat and Enozertinib, in mid-stage (Phase 2) clinical trials.
- Focused on a critical unmet need: overcoming cancer resistance with potential first-in-class or best-in-class therapies.
Insider Trading
STRONG SELL
4 insiders
6 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.